Vial Adaptors For Reconstitution Drug Market

Vial Adaptors For Reconstitution Drug Market Analysis

The Vial Adaptors For Reconstitution Drug Market size is estimated at USD 1.24 billion in 2025, and is expected to reach USD 1.69 billion by 2030, at a CAGR of 6.29% during the forecast period (2025-2030).

Factors such as the increasing prevalence of chronic and infectious diseases, the rising geriatric population, and increasing awareness of the advantages of vial adaptors are expected to boost market growth during the forecast period.

The growing burden of chronic diseases such as multiple sclerosis, diabetes, and rheumatoid arthritis is expected to boost the need for effective drugs, propelling the demand for vial adaptors to enable the safe, rapid transfer and reconstitution of drugs between vials. For instance, according to the World Health Organization’s August 2023 update, more than 2.8 million people globally have MS, including 1 million in the United States in 2022.

Additionally, as per 2022 updated data published by the International Diabetes Federation, the number of population expected to be diagnosed with diabetes will reach 643 million and 784 million by 2030 and 2045, respectively. Thus, the expected increase in the diabetic population fuels the need for vial adaptors for reconstituting or mixing insulin or other injectable medications, thereby boosting market growth.

Various research studies were conducted to estimate cancer incidence worldwide. For instance, per an article published in the Indian Journal of Medical Research in March 2023, India recorded an estimated 1 million incident cases of cancer in 2022. In addition, the incidence of cancer cases is estimated to increase by 12.8% in 2025 compared to the previous year. The rising number of cancer patients necessitates chemotherapy drugs, driving the demand for vial adaptors. These adaptors are crucial for preparing and administering injectable chemotherapy drugs, especially as many of these drugs are in powdered form within vials. This is anticipated to bolster market growth during the forecast period.

Additionally, the number of populations suffering from autoimmune diseases is increasing due to changes in environmental factors. For instance, according to 2023 data published by the European Congress of Rheumatology (EULAR), one in 10 individuals in the United Kingdom suffered from autoimmune diseases, and these cases increased over time. Vial adaptors play a crucial role in preparing and administering injectable drugs. This is mainly for autoimmune drugs like monoclonal antibodies and other biological therapies, which are typically supplied in vials as lyophilized powders or concentrated solutions. Given that these drugs often need to be reconstituted with a diluent before being administered, the market’s demand for vial adaptors is expected to increase during the forecast period.

The burden of metabolic disorders is increasing worldwide due to behavioral changes in lifestyles, leading to long-term health problems and expensive treatments. For instance, as per the World Obesity Atlas 2023, the prevalence of obesity (BMI ≥30kg/m²) alone was anticipated to rise from 14% to 24% among the population from 2020 to 2035, affecting nearly 2 billion adults, children, and adolescents by 2035. The overweight population has a higher risk of developing metabolic conditions due to high cholesterol, insulin resistance, and high blood pressure, fueling the demand for effective drugs. The availability of peptide hormones or receptor agonists in powder form raises the demand for safe and sterile transfer of the diluent into the drug vial, which is expected to propel the demand for vial adaptors in the market during the forecast period.

Therefore, owing to factors such as the growing burden of chronic and infectious diseases, the market studied is expected to grow during the forecast period. However, the availability of substitutes is expected to hinder the growth of the market during the forecast period.

Vial Adaptors For Reconstitution Drug Market Trends

Infectious Diseases Segment is Expected to Hold a Significant Market Share During the Forecast Period

• Vial adapters are used in the reconstitution of drugs designed for the treatment of infectious diseases, as maintaining sterility during the reconstitution process is necessary to prevent contamination and ensure the effectiveness of the medication. These adapters minimize the risk of contamination by reducing the number of needle insertions required during preparation.
• The infectious disease segment is anticipated to witness significant growth during the forecast period owing to factors such as the growing incidence and prevalence of various infectious diseases boosting the demand for effective drugs in the market.
• Additionally, advantages offered by vial adapters, such as their user-friendly nature, ease of preparing injectable medications, their use in treating infectious diseases according to the prescribed guidelines, facilitating the mixing process, and ensuring proper reconstitution of the drugs before administration to patients, are expected to fuel their adoption, thereby contributing to the segment’s growth.
• The high burden of infectious diseases among the population raises the need for early and effective therapeutics, which increases the adoption of vial adapters for safely and efficiently transferring medications between vials and syringes. This is anticipated to augment the segment’s growth. For instance, according to data published by the government of the United Kingdom in April 2024, about 1,196 people were diagnosed with tuberculosis in the first quarter of 2024, registering an increase of 7.5% compared to the same quarter in 2023. In addition, the number of people notified with tuberculosis increased in London (6.4% increase), Northwest (7.0% increase), Southeast (28.1% increase), West Midlands (33.6% increase), and Yorkshire and the Humber (17.7% increase) in the first quarter of 2024 compared to the same quarter in 2023.
• The prevalence and incidence of sexually transmitted diseases (STDs) are increasing, which is primarily due to unprotected sexual encounters. For instance, in October 2023, the UK Health Security Agency (UKHSA) unveiled concerning data on sexually transmitted infections (STIs) and its chlamydia screening initiative. The report underscored a rise in diagnoses, with 392,453 new STIs reported in 2022, prominently featuring gonorrhea and syphilis. This marked a 23.8% surge from the previous year. Gonorrhea cases spiked to 82,592 in 2022, a notable 50.3% increase from the 54,961 cases recorded in England the year prior. The need for effective antibiotic and antiviral preparation for the treatment augments the demand for vial adapters for safe and sterile transfer of the liquid in the vial to maintain its sterility, thus boosting segment growth.
• Various research studies were conducted to determine the effectiveness of vial adapters in maintaining the sterility of single-use vials. For instance, in August 2022, the Journal of Hematology Oncology Pharmacy highlighted the efficacy of vial adapters in preserving the sterility of single-use vials. The study found that closed-system drug-transfer device (CSTD) system vial adapter access devices, along with syringe adapters, maintained microbial sterility in drug vials even after nine days of repeated use. This finding suggested that vial adapters could extend the shelf life of partially used vials. Consequently, the anticipated safety and efficacy of vial adapters are likely to drive their adoption, thereby propelling market growth.
• Hence, owing to the high burden of tuberculosis and sexually transmitted diseases among the population and growing research studies related to vial adapters in maintaining sterility, the segment is expected to grow during the forecast period.

North America is Expected to Hold a Significant Market Share During the Forecast Period

• North America is expected to register a significant market share during the forecast period owing to factors such as the growing burden of chronic and infectious diseases among the population, which propels the demand for effective therapeutics.
• The rise in the geriatric population, who are more prone to develop various chronic and infectious diseases owing to weak immunity and age-related changes in the body, further boosts the demand for novel drugs. In addition, the rising awareness regarding the advantages of viral adapters is raising their adoption for the reconstitution of drugs, which is expected to drive the market’s growth in the region.
• The increasing incidence of chronic diseases is driving the demand for novel treatment, further accelerating the development of drugs in the market. For instance, a study published in Frontiers in Public Health in January 2023 projected that over 143 million Americans aged 50 years and above are expected to suffer from at least one chronic disease by 2050.
• Similarly, according to the American Cancer Society 2024 update, about 2.0 million new cancer cases are expected to be diagnosed in the United States in 2024. Around 5,480 cases of new cancer are likely to be identified in the United States daily. This is anticipated to fuel the demand for sterile and contamination-free reconstitution of the drugs in the market, propelling the adoption of vial adapters during the forecast period.
• Furthermore, there is a surge in the number of autoimmune and metabolic diseases, propelling the demand for drugs and boosting the adoption of vial adapters for safe and sterile transfer of the drugs in injections and vials. For instance, as per data published by Multiple Sclerosis Canada in 2023, on average, about 12 Canadians were diagnosed with multiple sclerosis every day.
• According to data published by the government of Canada in March 2023, almost two in three adults and one in three children and youth were overweight or obese in Canada in 2023. Being overweight raises the risk of developing several chronic diseases, such as cardiovascular disease, diabetes, and cancer, which is projected to foster the country’s market growth during the study period.
• Therefore, owing to factors such as the high burden of multiple sclerosis, obesity, cancer, and other chronic diseases, the market studied is anticipated to witness significant growth during the forecast period.

Vial Adaptors For Reconstitution Drug Industry Overview

The vial adaptors for reconstitution drug market is moderately competitive and consists of several major players. Some of the market players include Miltenyi Biotec, Baxter, West Pharmaceutical Services Inc., B. Braun Medical Inc., and Simplivia Healthcare Ltd.

Vial Adaptors For Reconstitution Drug Market Leaders

Vial Adaptors For Reconstitution Drug Market News

• December 2023: West Pharmaceutical Services Inc. launched a Vial2Bag Advanced 13-mm admixture device providing options for the reconstitution and transfer of a drug. The integrated vial adapter makes it possible to reconstitute and/or administer drugs to adolescent and adult patients before administration.
• December 2023: Teva Pharmaceutical Industries filed a patent for a vial adaptor that improves the connection between a syringe and a vial. The adaptor includes a syringe connection port, a vial connection port with a skirt and spike, a conduit for fluid flow, and a valve for controlling fluid flow.